{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.1"},{"groupId":"OG001","value":"62.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"241"}],"units":"Participants"}],"description":"Percentage of participants who died among TC1/2/3 or IC1/2/3 subgroup of PP-ITT were reported. TC1 = presence of discernible programmed death-ligand 1 (PD-L1) staining of any intensity in \\>/=1% and \\<5% TCs; TC2: presence of discernible PD-L1 staining of any intensity in \\>/=5% and \\<50% TCs; TC3 = presence of discernible PD-L1 staining of any intensity in \\>/=50% TCs; IC1 = presence of discernible PD-L1 staining of any intensity in ICs covering between \\>/=1% and \\<5% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC2 = presence of discernible PD-L1 staining of any intensity in ICs covering between \\>/=5% and \\<10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma; IC3 = presence of discernible PD-L1 staining of any intensity in ICs covering \\>/=10% of tumor area occupied by tumor cells, associated intratumoral, and contiguous peri-tumoral desmoplastic stroma.","groups":[{"description":"Docetaxel 75 milligrams per square meter (mg/m\\^2) was administered intravenously (IV) on Day 1 of each 21-day cycle until disease progression, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG000","title":"Docetaxel"},{"description":"Atezolizumab 1200 mg was administered IV on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit, death, unacceptable toxicity, withdrawal of consent, or study termination by sponsor, whichever occurred first.","id":"OG001","title":"Atezolizumab"}],"paramType":"NUMBER","populationDescription":"TC1/2/3 or IC1/2/3 subgroup within PP included ITT participants with the corresponding programmed death-ligand 1 (PD-L1) expression status.","reportingStatus":"POSTED","timeFrame":"Baseline until death due to any cause (up to approximately 2.25 years)","title":"Percentage of Participants Who Died: Tumor Cells (TC)1/2/3 or Tumor-Infiltrating Immune Cells (IC)1/2/3 Subgroup of PP","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}